PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28692737
OWN - NLM
STAT- MEDLINE
DA  - 20170710
DCOM- 20170714
LR  - 20170714
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 58
IP  - 9
DP  - 2017 Jul 01
TI  - An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring.
PG  - 3425-3431
LID - 10.1167/iovs.16-21377 [doi]
AB  - Purpose: The purpose of this study was to develop a topical matrix
      metalloproteinase inhibitor preparation for antiscarring therapy. Methods: The
      broad spectrum matrix metalloproteinase inhibitor ilomastat was formulated using 
      2-hydroxypropyl-beta-cyclodextrin in aqueous solution. In vitro activity of
      ilomastat-cyclodextrin (ilomastat-CD) was examined using fibroblasts seeded in
      collagen. Permeation of ilomastat-CD eye drop through pig eye conjunctiva was
      confirmed using Franz diffusion cells. Ilomastat-CD eye drop was applied to
      rabbit eyes in vivo, and the distribution of ilomastat in ocular tissues and
      fluids was determined by liquid chromatography-mass spectroscopy. Results: The
      aqueous solubility of ilomastat-CD was approximately 1000 mug/mL in water and
      1400 mug/mL in PBS (pH 7.4), which is greater than ilomastat alone (140 and 160
      mug/mL in water and PBS, respectively). The in vitro activity of ilomastat-CD to 
      inhibit collagen contraction in the presence of human Tenon fibroblast cells was 
      unchanged compared to uncomplexed ilomastat. Topically administered ilomastat-CD 
      in vivo to rabbit eyes resulted in a therapeutic concentration of ilomastat being
      present in the sclera and conjunctiva and within the aqueous humor. Conclusions: 
      Ilomastat-CD has the potential to be formulated as an eye drop for use as an
      antifibrotic, which may have implications for the prevention of scarring in many 
      settings, for example glaucoma filtration surgery.
FAU - Mohamed-Ahmed, Abeer H A
AU  - Mohamed-Ahmed AHA
AD  - UCL School of Pharmacy, London, United Kingdom 2UCL Institute of Ophthalmology,
      London, United Kingdom.
FAU - Lockwood, Alastair
AU  - Lockwood A
AD  - UCL School of Pharmacy, London, United Kingdom 2UCL Institute of Ophthalmology,
      London, United Kingdom.
FAU - Li, He
AU  - Li H
AD  - UCL Institute of Ophthalmology, London, United Kingdom.
FAU - Bailly, Maryse
AU  - Bailly M
AD  - UCL Institute of Ophthalmology, London, United Kingdom.
FAU - Khaw, Peng T
AU  - Khaw PT
AD  - UCL Institute of Ophthalmology, London, United Kingdom 3The National Institute
      for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital 
      NHS Foundation Trust, London, United Kingdom.
FAU - Brocchini, Steve
AU  - Brocchini S
AD  - UCL School of Pharmacy, London, United Kingdom 2UCL Institute of Ophthalmology,
      London, United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Indoles)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (Ophthalmic Solutions)
RN  - 9007-34-5 (Collagen)
RN  - I0403ML141 (ilomastat)
SB  - IM
MH  - Animals
MH  - Aqueous Humor/metabolism
MH  - Biological Availability
MH  - Cells, Cultured
MH  - Cicatrix/*drug therapy
MH  - Collagen/drug effects
MH  - Conjunctiva/metabolism
MH  - Cornea
MH  - Fibroblasts/drug effects
MH  - Humans
MH  - Indoles/chemistry/pharmacokinetics/*pharmacology
MH  - Matrix Metalloproteinase Inhibitors/chemistry/pharmacokinetics/*pharmacology
MH  - Ophthalmic Solutions
MH  - Sclera/metabolism
MH  - Solubility
MH  - Swine
EDAT- 2017/07/12 06:00
MHDA- 2017/07/15 06:00
CRDT- 2017/07/11 06:00
AID - 2643483 [pii]
AID - 10.1167/iovs.16-21377 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3425-3431. doi:
      10.1167/iovs.16-21377.